22 September 2021
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 20 September 2021, the following PDMRs acquired ordinary shares of 1p each in the Company pursuant to awards granted to them on 26 October 2018 under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The vesting of the awards was subject to the achievement of performance conditions which were satisfied to the extent that the awards vested at 73.8%. Ian Page and Tony Griffin sold sufficient of the shares they acquired in order to fund the resulting tax liability. In accordance with the Company's Directors' Remuneration Policy, the remaining shares must be retained for a period of two years from the date of vesting.
| Name | Capacity | Shares acquired | Shares Sold | Sale Price per share | Total beneficial shareholding following this announcement | Percentage of issued share capital |
| Ian Page | Director | 34,071 | 16,062 | £52.365113 | 358,021 | 0.331% |
| Tony Griffin | Director | 10,659 | 5,346 | £52.365113 | 33,463 | 0.031% |
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
Notification of Dealing Forms
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page
| |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR
| |
| b) | Initial notification/ amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82
| |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
| b) | Nature of the transaction | Acquisition of shares pursuant to the Company's Long Term Incentive Plan
| |
| c) | Price(s) and volumes(s) | Price(s) £Nil Cost | Volume(s) 34,071 |
| d) | Aggregated information - Aggregate volume - Price |
N/A | |
| e) | Date of the transaction | 2021.09.20 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page
| |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR
| |
| b) | Initial notification/ amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82
| |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
| b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability
| |
| c) | Price(s) and volumes(s) | Price(s) £52.365113 | Volume(s) 16,062 |
| d) | Aggregated information - Aggregate volume - Price - Total |
16,062
£52.365113 £841,088.45 | |
| e) | Date of the transaction | 2021.09.21 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Tony Griffin
| |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR
| |
| b) | Initial notification/ amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
| b) | Nature of the transaction | Acquisition of shares pursuant to the Company's Long Term Incentive Plan
| |
| c) | Price(s) and volumes(s) | Price(s) £nil | Volume(s) 10,659 |
| d) | Aggregated information - Aggregate volume - Price |
N/A | |
| e) | Date of the transaction | 2021.09.20 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Tony Griffin
| |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR
| |
| b) | Initial notification/ amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
| b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability
| |
| c) | Price(s) and volumes(s) | Price(s) £52.365113 | Volume(s) 5,346 |
| d) | Aggregated information - Aggregate volume - Price - Total |
5,346
£52.365113 £279,943.89 | |
| e) | Date of the transaction | 2021.09.21 | |
| f) | Place of the transaction | London Stock Exchange | |
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
